Kanghong pharmaceutical gains drug registration for diabetic neuropathy treatment

Chengdu Kanghong Pharmaceutical Group Co., Ltd. recently announced it has received a drug registration certificate for Epalrestat Tablets from the National Medical Products Administration. The drug, a 50mg tablet, is indicated for diabetic peripheral neuropathy and is classified as a Class 3 chemical drug.

Epalrestat is a reversible, non-competitive aldose reductase inhibitor, selectively acting on aldose reductase. Clinical studies have shown its ability to inhibit sorbitol accumulation in red blood cells of diabetic peripheral neuropathy patients, improving subjective symptoms and neurological dysfunction compared to control groups. This approval enriches the company’s product line.

The company cautioned investors that the production and sales of pharmaceutical products are subject to potential uncertainties arising from national policies and market environment changes. Investors are advised to exercise caution in their investment decisions.